Skip to content
Lower risk Drug recall · FDA · Published February 28, 2018

Osmotica Methylphenidate Tablets 36mg Recall: Subpotent Drug Risk

Osmotica recalls 36mg Methylphenidate ER tablets due to subpotent drug content. Affected lots: 170231B-170234A. Consumers should contact pharmacy for replacement.

🇺🇸 FDA recall #D-0581-2018DrugOsmotica ›
Take action

Contact the company

Recalling firmOsmotica Pharmaceutical Corp895 Sawyer Rd · Marietta, GA 30062-2257
✎ GovInfoNow plain-language explainer

Osmotica is recalling 36mg Methylphenidate Hydrochloride Extended-release Tablets that contain less active ingredient than labeled. This means the medication may not work as intended for patients needing treatment. Read more at govinfonow.com/recall/40797-osmotica-methylphenidate-tablets-36mg-recall-subpotent-drug-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/40797-osmotica-methylphenidate-tablets-36mg-recall-subpotent-drug-risk · Updated October 7, 2026 · FDA enforcement record: FDA #D-0581-2018

Cite this page

“Osmotica Methylphenidate Tablets 36mg Recall: Subpotent Drug Risk.” GovInfoNow, updated October 7, 2026. https://govinfonow.com/recall/40797-osmotica-methylphenidate-tablets-36mg-recall-subpotent-drug-risk. Based on FDA recall #D-0581-2018 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0581-2018%22&limit=1).

The FDA announced on Feb. 28, 2018, that Osmotica Pharmaceutical Corp voluntarily recalled Methylphenidate Hydrochloride Extended-release Tablets due to subpotency risks. The agency stated the recall was initiated by the firm.

How to tell if you have it

  • Brand: Osmotica
  • Product: Methylphenidate Hydrochloride Extended-release Tablets, USP, 36 mg, 100-count bottle
  • NDC: 13811-708-10
  • Lots: 170231B, 170232A, 170233A, 170234A
  • Manufacturer: Trigen Laboratories, LLC

The hazard

The FDA said the 100-count product bottles labeled as Methylphenidate HCL ER Tablets 36 mg were found to contain 27 mg Methylphenidate HCL ER Tablets. This subpotency issue constitutes a Class III recall.

Context

GovInfoNow's records show Osmotica Pharmaceutical Corp has two other recalls on record since Sept. 16, 2013. A Dec. 18, 2017, recall involved Methylphenidate Tablets for subpotent drug risk. Other recent recalls of similar products include Unichem busPIRone 5mg Tablets (April 13, 2026), IntegraDose Vasopressin (May 18, 2026), and Avantor Magnesium Chloride API (March 31, 2026).

How to tell if you have this one

Check for the product name 'Methylphenidate Hydrochloride Extended-release Tablets, USP, 36 mg' on the label. Look for lot numbers 170231B, 170232A, 170233A, or 170234A on the bottle.

  • Brand
    Osmotica
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Contact Pharmacy

    Reach out to your pharmacy to get a replacement product with the correct dosage.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 14 months after the firm started it.

1. Firm started the recall: Feb 28, 201812. FDA classified it Class III: Mar 6, 201823. Published in FDA’s Enforcement Report: Mar 14, 201834. FDA terminated the recall: May 1, 2019420182019
  1. Firm started the recall
  2. FDA classified it Class III
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0581-2018 (February 28, 2018) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0581-2018 to see it in context.
  • Plain-language summary written by qwen3:4b on October 7, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA